NLS Intellectual Property

Orexo announces that the United States District Court for the District of Delaware ruled in Orexo’s favor in one of the patent infringement litigations against Actavis Elizabeth LLC regarding Zubsolv in the US. Orexo commenced this patent infringement litigation in June 2014 in response to Actavis’s Abbreviated New Drug Application seeking approval to market and […]

InDex Pharmaceuticals Holding has announced that a new method of use patent for the drug candidate cobitolimod will be granted by the United States Patent and Trademark Office (USPTO). The patent provides additional protection for the use of certain dosage regimens of cobitolimod for treating chronic active ulcerative colitis in patients that are not responding […]

Modus Therapeutics has been granted two patents in the US covering its proprietary compound sevuparin. More specifically the two patents have been granted claims for the substance sevuparin per se and a manufacturing method for producing sevuparin (U.S. Patent no. 9,480,701) as well as its use in e.g. Sickle Cell Disease (U.S. Patent No. 9.480,702). […]

Targovax announces the grant of European Patent no 2,379,586. This composition of matter patent protects Targovax’s lead product from its ONCOS platform, the oncolytic viral product ONCOS-102 and expires in 2029. A US patent covering ONCOS-102 was granted in May 2016. Targovax’s proprietary ONCOS platform generates novel oncolytic viruses, an emerging class of biological therapy. […]

Dilaforette Holding AB, a clinical-stage drug development and Karolinska Development portfolio company, announces its name change to Modus Therapeutics Holding AB and its intention to undertake an Initial Public Offering (IPO). A rights issue is planned in connection with the IPO in order to finance the further clinical development of the company’s lead candidate sevuparin for […]

BioInvent International announces that it has been granted additional patent protection in Japan, Russia and China for BI-505, its lead immune-oncology programme currently in Phase II for the treatment of multiple myeloma. These patents cover the use of BI-505 in the treatment of patients previously treated for cancer that have either not responded or subsequently […]